Compare Crispr Therapeutics AG (CRSP) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Lowe`s Companies Inc — how do they compare? Crispr Therapeutics AG trades at $50.73 (market cap $5.06B), while Lowe`s Companies Inc trades at $189 (market cap $101.85B). The key difference: Lowe`s Companies Inc is far larger — about 20.1× Crispr Therapeutics AG's market cap, and Lowe`s Companies Inc pays a 2.75% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Lowe`s Companies Inc for 98 Days on average.
| CRSP | LOW | |
|---|---|---|
Market Cap | $5.06B | $101.85B |
Volume | 1,678,371 | 2,370,093 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $287.39 |
52-Week Low | $44.34 | $179.50 |
Typical Hold Time | 77 Days | 98 Days |
Enterprise Value | $3.48B | $140.70B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 6.59% over 24 hours amid bearish technical signals. The company shows negative profitability metrics with -4,101.26% net income margin and -$581.60M net loss for 2025, though Q2 2026 EPS beat expectations. Recent news highlights upcoming clinical data presentations and commercial progress with CASGEVY gene therapy. Cash flow remains negative from operations but positive overall due to financing activities.
While analyst consensus remains bullish with 57.9% buy ratings and $67.83 price target, significant execution risks persist. The stock faces pressure from sustained cash burn and competitive threats, but potential catalysts include upcoming clinical data readouts and CASGEVY revenue growth. Investors should weigh high-risk biotech volatility against breakthrough therapy potential.
Lowe's Companies (LOW) trades at $188.85, up 2.81% on the day, with a bearish technical signal but strong analyst support. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue declined to $83.67 billion in 2025, though net income margin remains healthy at 7.35%. Recent news highlights drone delivery innovation with DoorDash and Alphabet, aiming to enhance customer convenience amid a challenging home improvement market.
The outlook is mixed: analyst consensus is bullish with a $244.09 price target, but technical indicators and industry headwinds pose risks. Investment opportunity lies in valuation metrics like a P/E of 15.35 and dividend consistency, while risks include high debt levels and sensitivity to housing market trends. Earnings performance and execution of new initiatives will be critical for stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
